The effect of alpha-adrenergic blocking drugs on reducing the excitatory symptoms of ureteral stent placement

The effect of alpha-blocker drugs on reducing the irritating symptoms caused by ureteral stent placement in patients undergoing surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201006048950N3

Enrollment

Registered

2022-01-17

Start date

2022-04-21

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral canal stenosis. Displacement of urinary stent

Interventions

Intervention 1: Intervention group 1: Patients are receiving trazosin drug. Intervention 2: Intervention group 2: Patients are receiving tamsulosin drug.

Eligibility

Sex/Gender

All

Age

No minimum to 81 Years

Inclusion criteria

Inclusion criteria: lack of Underlying disease, especially nephrogenic cardiovascular problems, allergies, other urological diseases, urinary retention, diabetes, malignancy in the urinary tract, chronic pelvic pain syndrome, lower urinary tract symptoms No drug addiction Age less than 81 years Informed consent One-sided G stent placement

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Reduction of stent-dependent stimulus symptoms. Timepoint: Take drug:one dose daily for 4-6 weeks. Method of measurement: Questionnaires 1- Symptoms related to stent placement (USSQ) 2- International Prostate Symptoms Questionnaire (IPSS) 3- Quality of Life Questionnaire (QOL).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahboobeh Khosravani

Arak University of Medical Sciences

mahboobkhosravani@gmail.com+98 86 3224 0507

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026